Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.06.2023 | Case report

Trametinib/vemurafenib

Various toxicities: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Wang Z, et al. Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report. Frontiers in Oncology 11: 25 Jan 2022. Available from: URL: http://doi.org/10.3389/fonc.2021.801320 Wang Z, et al. Vemurafenib Combined With Trametinib Significantly Benefits the Survival of a Patient With Stage IV Pancreatic Ductal Adenocarcinoma With BRAF V600E Mutation: A Case Report. Frontiers in Oncology 11: 25 Jan 2022. Available from: URL: http://​doi.​org/​10.​3389/​fonc.​2021.​801320
Metadaten
Titel
Trametinib/vemurafenib
Various toxicities: case report
Publikationsdatum
01.06.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-41660-1

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Multiple drugs

Case report

Everolimus

Case report

Multiple drug

Case report

Antineoplastics